Cocaine- and amphetamine-regulated transcript is increased in Huntington disease

Movement Disorders

Volumn 22, Issue 13, 2007, Pages 1952-1954

  Björkqvist, Maria ^a   Leavitt, Blair R ^b,c   Nielsen, Jörgen E ^d,e   Landwehrmeyer, Bernhard ^f   Ecker, Daniel ^f   Mulder, Hindrik ^a   Brundin, Patrik ^a   Petersén, Åsa ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BC CHILDREN S HOSPITAL   (Canada)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Rigshospitalet   (Denmark)

^f UNIVERSITY OF ULM   (Germany)

Author keywords

Anxiety; Biomarker; CART; CSF; Hypothalamus

Indexed keywords

COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE;

ADULT; AMYGDALOID NUCLEUS; ANXIETY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOOD INTAKE; GENE MUTATION; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMUS; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION;

ANXIETY; BIOLOGICAL MARKERS; BRAIN; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENERGY METABOLISM; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROTRANSMITTER AGENTS; RADIOIMMUNOASSAY; REFERENCE VALUES; WEIGHT LOSS;

EID: 36249001659     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21447     Document Type: Article

References (18)

1. Kassubek J, Juengling FD, Kioschies T, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004;75:213-220.
2. Kremer HP, Roos RA, Dingjan G, Marani E, Bots GT. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol 1990;49:371-382.
3. Kremer HP, Roos RA, Dingjan GM, Bots GT, Bruyn GW, Hofman MA. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci Lett 1991;132:101-104.
4. Petersen A, Gil J, Maat-Schieman ML, et al. Orexin loss in Huntington's disease. Hum Mol Genet 2005;14:39-47.
5. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
6. Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Curr Opin Neurol 2005;18:698-705.
7. Petersen A, Bjorkqvist M. Hypothalamaic-endocrine changes in Huntington's disease. Eur J Neurosci 2006;24:961-967.
8. Robbins AO, Ho AK, Barker RA. Weight changes in Huntington's disease. Eur J Neurol 2006;13:e7.
9. Kishi T, Elmquist JK. Body weight is regulated by the brain: a link between feeding and emotion. Mol Psychiatry 2005;10:132-146.
10. Kuhar MJ, Adams S, Dominguez G, Jaworski J, Balkan B. CART peptides. Neuropeptides 2002;36:1-8.
11. Stanek LM. Cocaine- and amphetamine-related transcript (CART) and anxiety. Peptides 2006;27:2005-2011.
12. Larsen PJ, Hunter RG. The role of CART in body weight homeostasis. Peptides 2006;27:1981-1986.
13. Vicentic A, Jones DC. The CART system in appetite and drug addiction. J Pharmacol Exp Ther 2007;320:499-506.
14. Vicentic A. CART peptide diurnal variations in blood and brain. Peptides 2006;27:1942-1948.
15. Miraglia del Giudice E, Santoro N, Fiumani P, Dominguez G, Kuhar MJ, Perrone L. Adolescents carrying a missense mutation in the CART gene exhibit increased anxiety and depression. Depress Anxiety 2006;23:90-92.
16. Morales LM, Estevez J, Suarez H, Villalobos R, Chacin de Bonilla L, Bonilla E. Nutritional evaluation of Huntington disease patients. Am J Clin Nutr 1989;50:145-150.
17. Farrer LA, Yu PL. Anthropometric discrimination among affected, at risk, and not-at-risk individuals in families with Huntington disease. Am J Med Genet 1985;21:307-316.
18. Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velasquez L. Assessment of the nutrition status of patients with Huntington's disease. Nutrition 2004;20:192-196.